Table 1 Baseline characteristics of the adherence and nonadherent groups.
From: Risk factors and reasons for romosozumab nonadherence in a case-control study
Adherence (n = 62) | Nonadherence (n = 69) | p-value | |
|---|---|---|---|
Age at first treatment (years) | 73.9 ± 10.9 | 74.6 ± 11.5 | 0.721a |
< 60 years | 8 (12.9%) | 5 (7.2%) | 0.464 |
60–69 years | 12 (19.4%) | 13 (18.8%) | |
70–79 years | 18 (29.0%) | 28 (40.6%) | |
≥ 80 years | 24 (38.7%) | 23 (33.3%) | |
Sex | |||
Female | 61 (98.4%) | 56 (81.2%) | 0.001 |
Male | 1 (1.6%) | 13 (18.8%) | |
Bone mass density (T-score)b | − 3.3 ± 0.9 | − 3.1 ± 0.9 | 0.320 |
Romosozumab expenses | |||
Full subsidy | 27 (43.5%) | 15 (21.7%) | 0.008 |
Self-payment | 35 (56.5%) | 54 (78.3%) | |
Fracture history within 1 year before romosozumab therapy | 17 (27.4%) | 12 (17.4%) | 0.167 |
History of orthopedic surgery | |||
None | 32 (51.6%) | 35 (50.7%) | 0.741 |
Within 1 year before treatment | 26 (41.9%) | 27 (39.1%) | |
During treatment | 4 (6.5%) | 7 (10.1%) | |
